[ad_1] Immunotherapy with pembrolizumab improves survival in patients with recurrent or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at ESMO 2018 Congress in Munich. The current standard treatment for …
Read More »Immunotherapy with pembrolizumab extends survival in metastatic recurrent head and neck cancer
